Blackstone and TPG completed their acquisition of Hologic, taking the molecular diagnostics company private after a deal valued at up to $18.3 billion announced in October 2025. Hologic shareholders will receive $76 per share in cash plus a contingent value right potentially worth up to $3 per share tied to global revenue targets in fiscal years 2026 and 2027. The firms said the company will be delisted from Nasdaq, and José Almeida has been named CEO effective immediately following leadership changes connected to the transaction. Hologic’s portfolio includes molecular diagnostics platforms and tests as well as breast and skeletal health products and gynecological offerings. For the diagnostics space, the close signals continued consolidation pressure as investors seek scale, technology integration, and long-term capital structures outside quarterly market constraints.